Drug intelligence / Profile preview

IntestAidIB

Development stage: Unknown
Lead developer: University of East London
Administration: Oral

Overview

IntestAidIB is a nucleotide-based nutraceutical supplement developed by researchers at the University of East London for the management of Irritable Bowel Syndrome (IBS). The formulation provides dietary nucleotides, which are essential building blocks for the rapid turnover and repair of cells in the gastrointestinal (GI) tract and the immune system. By supporting gut mucosal integrity—specifically by increasing villus height and crypt depth—IntestAidIB aims to improve gut barrier function and alleviate IBS symptoms such as abdominal pain, bloating, and urgency. A randomized, double-blind, placebo-controlled crossover trial (ISRCTN67764449) demonstrated that the supplement provides modest, consistent improvements in most IBS symptoms with no reported side effects.

Brand names: IntestAidIB
Other names: IntestAid IB

Beyond the preview

Go deeper on IntestAidIB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntestAidIB.

Explore the full profile